Company Filing History:
Years Active: 2014-2019
Title: Renzo Nogarotto: Innovator in Tumor Marker Technologies
Introduction
Renzo Nogarotto is a distinguished inventor based in Siena, Italy. He has made significant contributions to the field of medical diagnostics, particularly in the identification of tumor markers. With a total of 3 patents, his work focuses on innovative methods for detecting and treating various types of tumors.
Latest Patents
Renzo Nogarotto's latest patents include groundbreaking inventions related to ovary tumor markers. One of his notable patents is centered on newly identified proteins that serve as markers for the detection of ovary tumors. These proteins can also act as therapeutic targets for treatment. Additionally, he has developed affinity ligands capable of selectively interacting with these markers, which can be utilized in tumor diagnosis and therapy. Another significant patent involves tumor markers for detecting malignancies in lung, colon, breast, and ovary tumors. This invention includes methods for screening tissue samples for malignancy, determining the presence of tumors in subjects, and screening test compounds as potential antitumor candidates. A diagnostic kit is also part of this innovative work.
Career Highlights
Throughout his career, Renzo has worked with various companies, including Externautics S.p.a. and Externautics Società a Responsabilità Limitata "società in Liquidazione". His experience in these organizations has contributed to his expertise in the field of medical diagnostics and tumor marker technologies.
Collaborations
Renzo Nogarotto has collaborated with notable professionals in his field, including Renata Grifantini and Piero Pileri. These collaborations have further enhanced his research and development efforts in tumor marker technologies.
Conclusion
Renzo Nogarotto is a prominent inventor whose work in tumor marker technologies has the potential to revolutionize cancer diagnostics and treatment. His innovative patents and collaborations reflect his commitment to advancing medical science.